T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity ...

At the BioTrinity Conference, experts champion government funding programmes to bridge gap the in UK venture capital ...

Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of ...

Apellis Pharmaceuticals has announced US FDA acceptance of the sNDA and the granting of priority review status to Empaveli ...

Amneal Pharmaceuticals and Shilpa Medicare have launched the new presentation of bortezomib, Boruzu, for subcutaneous or ...

The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.

Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma environment.

Plans outlined by HHS Secretary Robert F Kennedy, Jr look set to target jobs at the US Department of Health & Human Services (HHS).

But while platform trials have the potential to be more effective and less expensive than traditional trials, challenges ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib.

The establishment of NHS England (NHSE) to undertake functions previously the responsibility of the then Department of Health ...